Optimal timing of antiretroviral treatment initiation in HIV-positive children and adolescents: A multiregional analysis from Southern Africa, West Africa and Europe

International Journal of Epidemiology

Volumn 46, Issue 2, 2017, Pages 453-465

  Schomaker, Michael ^a   Leroy, Valeriane ^b   Wolfs, Tom ^c   Technau, Karl Günter ^d,e   Renner, Lorna ^f   Judd, Ali ^g   Sawry, Shobna ^h   Amorissani Folquet, Madeleine ⁱ   Noguera Julian, Antoni ^j   Tanser, Frank ^k,l   Eboua, Frančois ^m   Navarro, Maria Luisa ⁿ   Chimbetete, Cleophas ^o   Amani Bosse, Clarisse ^p   Warszawski, Josiane ^q   Phiri, Sam ^r   N'Gbeche, Sylvie ^s   Cox, Vivian ^t   Koueta, Fla ^u   Giddy, Janet ^v   Sygnaté Sy, Haby ^w   Raben, Dorthe ^x   Chêne, Geneviève ^y,z,aa   Davies, Mary Ann ^a   more..

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^f UNIVERSITY OF GHANA   (Ghana)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY OF THE WITWATERSRAND   (South Africa)

ⁱ UNIVERSITÉ FÉLIX HOUPHOUËT BOIGNY   (Côte d’Ivoire)

^j UNIVERSITY OF BARCELONA   (Spain)

^k UNIVERSITY OF KWAZULU NATAL   (South Africa)

^l UNIVERSITY OF KWAZULU NATAL   (South Africa)

^m University Hospital of Yopougon   (Côte d’Ivoire)

ⁿ HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^o Newlands Clinic   (Zimbabwe)

^p MTCT Plus Programme   (Côte d’Ivoire)

^q CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^r LIGHTHOUSE TRUST   (Malawi)

^s CePReF   (Côte d’Ivoire)

^t MÉDECINS SANS FRONTIÈRES   (Switzerland)

^u Charles De Gaulle Pediatric University Teaching Hospital   (Burkina Faso)

^v MCCORD HOSPITAL   (South Africa)

^w Albert Royer Hospital   (Senegal)

^x UNIVERSITY OF COPENHAGEN   (Denmark)

^y UNIVERSITÉ DE BORDEAUX   (France)

^z INSERM   (France)

^aa BORDEAUX UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Antiretroviral treatment; Causal inference; G formula; Paediatrics

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT;

ADOLESCENCE; CELLS AND CELL COMPONENTS; CHILD HEALTH; CHILD MORTALITY; COHORT ANALYSIS; CONFIDENCE INTERVAL; DISEASE TREATMENT; HEIGHT; HUMAN IMMUNODEFICIENCY VIRUS; MEDICINE; TIME DEPENDENT BEHAVIOR; WORLD HEALTH ORGANIZATION;

ADOLESCENT; AGE; ANTIRETROVIRAL THERAPY; ARTICLE; BODY HEIGHT; CD4 LYMPHOCYTE COUNT; CHILD; CHILD GROWTH; CHILDHOOD MORTALITY; CLINICAL EVALUATION; CLINICAL OUTCOME; COHORT ANALYSIS; CONFOUNDING VARIABLE; EARLY CHILDHOOD INTERVENTION; EUROPEAN; FEMALE; FOLLOW UP; GROWTH CURVE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SOUTH AFRICA; SOUTH AFRICAN; SOUTHERN EUROPE; TIME TO TREATMENT; TREND STUDY; WEST AFRICAN; WORLD HEALTH ORGANIZATION; AFRICA; AGE DISTRIBUTION; BODY WEIGHT; CLINICAL TRIAL; DEMOGRAPHY; EPIDEMIOLOGY; EUROPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; INFANT; MORTALITY; MULTICENTER STUDY; PRESCHOOL CHILD; SEX RATIO; STATISTICAL ANALYSIS; TIME FACTOR;

EUROPE; SOUTHERN AFRICA; WEST AFRICA;

ADOLESCENT; AFRICA, SOUTHERN; AFRICA, WESTERN; AGE DISTRIBUTION; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DATA INTERPRETATION, STATISTICAL; DEMOGRAPHY; EUROPE; FEMALE; HIV INFECTIONS; HUMANS; INFANT; MALE; SEX DISTRIBUTION; TIME FACTORS;

EID: 85028696291     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyw097     Document Type: Article

References (39)

1. WHO. Antiretroviral Therapy of HIV Infection in Infants and Children. 2006. http://www.who.int/hiv/pub/guidelines/en/
2. WHO. Antiretroviral Therapy for HIV Infection in Adults and Adolescents. 2006. http://www.who.int/hiv/pub/guidelines/en/
3. Prendergast AJ, Penazzato M, Cotton M et al. Treatment of young children with HIV infection: using evidence to inform policymakers. Plos Med 2012;9:e1001273
4. Puthanakit T, Bunupuradah T. Early versus deferred antiretroviral therapy in children in low-income and middle-income countries. Curr Opin HIV/AIDS 2010;5:12-17
5. Schomaker M. Implications of causal modelling studies on the question of when to start antiretroviral treatment in young children. SACEMA Q 2014. http://sacemaquarterly.com/wp-con tent/uploads/2014/11/Michael_Implications-of-article-1.pdf
6. Siegfried N, Davies MA, Penazzato M, Muhe LM, Egger M. Optimal time for initiating antiretroviral therapy (ART) in HIVinfected, treatment-naive children aged 2 to 5 years old. Cochrane Database Syst Rev 2013;10:CD010309
7. Turkova A, Webb RH, Lyall H. When to start, what to start and other treatment controversies in pediatric HIV infection. Paediatr Drugs 2012;14:361-76
8. Welch SB, Gibb D. When should children with HIV infection be started on antiretroviral therapy? Plos Med 2008;5:e73
9. Violari A, Cotton MF, Gibb DM et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008;359:2233-44
10. WHO. Antiretroviral Therapy for HIV Infection in Adults and Adolescents. 2010. http://www.who.int/hiv/pub/guidelines/en/
11. WHO. Antiretroviral Therapy for HIV Infection in Infants and Children. 2010. http://www.who.int/hiv/pub/guidelines/en/
12. WHO. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. 2013. http:// www.who.int/hiv/pub/guidelines/en/
13. Edmonds A, Yotebieng M, Lusiama J et al. The effect of highly active antiretroviral therapy on the survival of HIV-infected children in a resource-deprived setting: a cohort study. Plos Med 2011;8:e1001044
14. Puthanakit T, Ananworanich J, Vonthanak S et al. Cognitive Function and Neurodevelopmental Outcomes in HIV-infected Children Older Than 1 Year of Age Randomized to Early Versus Deferred Antiretroviral Therapy: The PREDICT Neurodevelopmental Study. Pediatr InfectDis J 2013;32:501-08
15. Puthanakit T, Saphonn V, Ananworanich J et al. Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, openlabel trial. Lancet Infect Dis 2012;12:933-41
16. Schomaker M, Davies MA, Malateste K et al. Growth and mortality outcomes for different antiretroviral therapy initiation criteria in children aged 1-5 years: a causal modelling analysis from West and Southern Africa. Epidemiology 2016;27:237-46
17. Schomaker M, Egger M, Ndirangu J et al. When to start antiretroviral therapy in children aged 2-5 years: a collaborative causal modelling analysis of cohort studies from southern Africa. Plos Med 2013;10:e1001555
18. WHO. Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV. 2015. http://www.who. int/hiv/pub/guidelines/en/
19. Danel C, Moh R, Gabillard D et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med 2015;373:808-22
20. Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med 2015;373:795-807
21. Daniel RM, De Stavola BL, Cousens SN. G-formula: Estimating causal effects in the presence of time-varying confounding ormediation using the g-computation formula. Stata J 2011;11:479-517
22. Robins J. A new approach to causal inference in mortality studies with a sustained exposure period-application to control of the healthy worker survivor effect. Math Modelling 1986;7:1393-512
23. Robins J, Hernan MA. Estimation of the causal effects of timevarying exposures. In: Fitzmaurice G, Davidian M, Verbeke G, Molenberghs G (eds). Longitudinal Data Analysis. London: Chapman Hall/CRC Press, 2009
24. Robins J, Hernan MA, Siebert U. Comparative quantication of health risks: global and regional burden of disease attributable to selected major risk factors. In: Ezzati M, Murray C, Lopez A (eds). Effects of Multiple Interventions. Geneva: World Health Organization, 2004
25. EggerM, Ekouevi DK,Williams C et al. Cohort Profile: The international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa. Int J Epidemiol 2012;41:1256-64
26. Fenner L, BrinkhofMWG, Keiser O et al. Early Mortality and Loss to Follow-up in HIV-Infected Children Starting Antiretroviral Therapy in Southern Africa. J Acquir Immune Defic Syndr 2010;54:524-32
27. Ekouevi DK, Azondekon A, Dicko F et al. 12-month mortality and loss-to-program in antiretroviral-treated children: The IeDEA pediatric West African Database to evaluate AIDS (pWADA), 2000-2008. BMC Public Health 2011;11:519
28. IeDEA Pediatric Working Group. A survey of paediatric HIV programmatic and clinical management practices in Asia and sub-Saharan Africa-the International epidemiologic Databases to Evaluate AIDS (IeDEA). J Int AIDS Soc 2013;16:17998
29. Sabin CA, Smith CJ, Monforte AD et al. Response to combination antiretroviral therapy: variation by age-The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group. AIDS 2008;22:1463-73
30. WHO. TheWHOChild Growth Standards. Geneva: WHO, 2008
31. Honaker J, King G, Blackwell M. Amelia II: A Program for Missing Data. J Stat Software 2011;45:1-47
32. Wood SN. Thin plate regression splines. J R Stat Soc B 2003;65:95-114
33. Wood SN. Generalized Additive Models: An Introduction with R. London: Chapman and Hall/CRC, 2006
34. Westreich D, Cole SR, Young JG et al. The parametric g-formula to estimate the effect of highly active antiretroviral therapy on incident AIDS or death. Stat Med 2012;31:2000-09
35. Young JG, Cain LE, Robins JM, O'Reilly EJ, Hernan MA. Comparative effectiveness of dynamic treatment regimes: an application of the parametric g-formula. Stat Biosci 2011;3:119-43
36. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation For Statistical Computing, 2014
37. Szubert AJ, Musiime V, Bwakura-Dangarembizi M et al. Pubertal development in HIV-infected African children on firstline antiretroviral therapy. AIDS 2015;29:609-18
38. Williams PL, Abzug MJ, Jacobson DL et al. Pubertal onset in children with perinatal HIV infection in the era of combination antiretroviral treatment. AIDS 2013;27:1959-70
39. Lodi S, Phillips A, Logan R et al. Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. Lancet HIV 2015;2:e335-43